Genometry, a gene technology company, has raised $3 million in venture capital, according to a new filing by the company with the Securities and Exchange Commission.

Genometry is a platform-technology company founded by a multidisciplinary team of genome scientists to commercialize a revolutionary genome-wide high-throughput low-cost gene-expression profiling method (L1000) for next-generation pharmaceutical discovery applications.

While working at the Broad Institute of MIT and Harvard University, GENOMETRY's founders discovered that by measuring the expression levels of approximately one thousand landmark genes, and using a computational model trained on more than one hundred thousand microarray experiments to infer the activity of the other nineteen thousand genes, it is possible to produce close approximations of gene-expression profiles in which the levels of all twenty thousand transcripts are explicitly measured.

L1000 Expression Profiling produces high-dimensional gene-expression profiles from crude cell lysates in 384-well plate format at a rate of thousands a day, and at only a fraction of the cost of conventional microarray-based methods. This enables the use of expression profiling at a scale never before possible.